Cambrian launches new subsidiary to develop mTOR inhibitors

Cambrian has added to its age-related disease portfolio via a deal with Novartis for a series of mTOR inhibitors that will be developed by newly launched subsidiary Tornado Therapeutics.

Cambrian Biopharma Inc. acquired exclusive, worldwide rights to a group of selective mTOR inhibitors from Novartis AG (NYSE:NVS; SIX:NOVN) for an undisclosed upfront payment. Novartis is also eligible for undisclosed milestones, plus royalties. ...